Yale School Of Medicine

Healio spoke with Daniel P. Petrylak, MD, about a presentation the American Urological Association meeting that focused on discontinuation rates of hormone therapy options among patients with advanced prostate cancer.

In this video, Daniel P. Petrylak, MD, discussed a presentation investigating androgen deprivation therapy plus upfront docetaxel in the treatment of patients 75 years or older with prostate cancer.

In this video, Michael Cecchini, MD, discussed the late-breaking phase 2 study presented at ASCO Annual Meeting on single-agent dostarlimab for patients with mismatch repair-deficient or microsatellite instability high rectal cancer.

Patients with pneumonia who were admitted to hospitals with high readmission rates had an elevated risk for in-hospital adverse events, according to a study published in JAMA Network Open.

In this video, Michael Cecchini, MD, discussed the late-breaking phase 3 PARADIGM trial presented at an ASCO Annual Meeting plenary session.

ATLANTA — Use of empagliflozin was associated with a nearly 40% reduced risk for nephrolithiasis among people with type 2 diabetes, according to data presented at ENDO 2022.

NEW ORLEANS — Nearly all participants with obesity without diabetes assigned tirzepatide experienced at least 5% weight loss over 72 weeks compared with placebo, with at least 20% weight loss in more than half with the highest 15 mg dose.

SAN FRANCISCO — In this video from the Arthroscopy Association of North America Annual Meeting, Andrew E. Jimenez, MD, discusses predictors of return to sport among high-level athletes who underwent hip arthroscopy.

Electronic health record-based alert informing providers about evidence-based medications for HFrEF vs. usual care in outpatient clinics.

Patients who underwent left atrial appendage closure with a next-generation device were significantly less likely to experience in-hospital major adverse events, including pericardial effusion, compared with an earlier-generation device.